Emergent BioSolutions announced that the U.S. Food and Drug Administration has listed “No Action Indicated” or NAI status classification for the company’s Baltimore Bayview manufacturing facility. Based on this outcome, the Baltimore Bayview facility is considered to be in an acceptable state of compliance with regard to current good manufacturing practices.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
- Emergent BioSolutions upgraded to Buy at Benchmark after ‘upbeat’ Q4 report
- Emergent BioSolutions upgraded to Buy from Hold at Benchmark
- Emergent BioSolutions sees Q1 revenue $200M-$250M, consensus $185.4M
- Emergent BioSolutions sees FY24 revenue $900M-$1.1B, consensus $1.18B
